文献速递区域麻醉与超声疼痛医学

单次收肌管阻滞联合神经周围地塞米松对比连续收肌管导管用于全膝关节置换术:随机对照试验

Single-injection adductor canal block with perineural dexamethasone versus continuous adductor canal catheter for total knee arthroplasty: a randomized controlled trial.
PubMed 文献 · Reg Anesth Pain Med · 2026-09-04

这项随机对照试验纳入94例初次单侧全膝关节置换术患者,比较单次收肌管阻滞联合神经周围地塞米松与连续收肌管导管输注对术后24-48小时阿片类药物消耗的影响。结果显示两组在术后24-48小时阿片消耗无统计学差异(中位数30 mg vs 38.8 mg,p=0.213),在麻醉后监护室阿片消耗也无显著差异(p=0.081)。结论认为在包含神经周围地塞米松、iPACK阻滞、关节周围浸润等多模式镇痛方案下,连续导管未减少术后24-48小时阿片消耗。

要点

  • 连续收肌管导管未显著减少全膝关节置换术后24-48小时阿片消耗。
  • 在综合多模式镇痛方案下,单次阻滞联合地塞米松与连续导管效果相当。
  • 导管相关扭结发生率为7%,均为短暂性事件。

核心结论

  • 在包含神经周围地塞米松、iPACK阻滞、关节周围浸润、口服镇痛药和远程医疗疼痛咨询的综合多模式镇痛方案下,连续收肌管导管输注未减少初次全膝关节置换术后24-48小时阿片消耗。

研究设计与样本

  • 参与者盲法和评估者盲法的随机对照试验,纳入94例接受初次单侧全膝关节置换术的患者。

主要发现

  • 术后24-48小时阿片消耗在连续输注组与单次注射组间无统计学显著差异(中位数30 mg vs 38.8 mg,中位数差95%CI -22.50至7.00 mg,p=0.213)。
  • 预先设定的次要结局麻醉后监护室阿片消耗两组间也无显著差异(22.5 mg vs 15 mg,中位数差95%CI 0.00至13.50 mg,p=0.081)。
  • 导管相关扭结发生在连续输注组的7%,单次注射组为0%,所有事件均为短暂性。
  • 患者满意度、住院时间和功能恢复方面未观察到统计学显著差异。

关键数值与推荐

  • 单次注射组:收肌管阻滞使用0.25%布比卡因15 mL联合神经周围地塞米松2 mg。
  • 连续输注组:单次注射收肌管阻滞(0.25%布比卡因15 mL)后置入连续收肌管导管,输注0.2%罗哌卡因8 mL/小时共50小时。
  • 两组均接受标准化多模式镇痛方案,包括iPACK阻滞、关节周围浸润和口服镇痛药。

临床怎么用

  • 在已采用神经周围地塞米松、iPACK阻滞和关节周围浸润的综合多模式镇痛方案中,连续收肌管导管未必进一步减少术后24-48小时阿片消耗。
  • 临床决策置入连续收肌管导管时需权衡其潜在获益与导管相关扭结等风险。

局限性

  • 样本量94例,结论需在更大样本中验证。
  • 连续导管在脊麻消退时启动,可能影响早期镇痛效果评估。
  • 所有其他结局为预先计划的探索性分析,非主要终点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The adductor canal block (ACB), known for its motor-sparing properties, has gained popularity as part of the multimodal analgesic regimen in total knee arthroplasty (TKA) patients. However, the duration of single-injection blocks is limited, potentially contributing to rebound pain after the first 24 hours. This study evaluates whether extending block duration using a continuous peripheral nerve catheter reduces opioid consumption during the 24-48 hour period following TKA. METHODS: This participant-blinded and assessor-blinded randomized controlled trial included 94 patients undergoing primary, unilateral TKA. Patients were randomized into two groups: the single-injection group received a single-injection ACB (15 mL of 0.25% bupivacaine) with 2 mg perineural dexamethasone; the continuous infusion group received a single-injection ACB (15 mL of 0.25% bupivacaine) followed by a continuous adductor canal catheter infusing 0.2% ropivacaine at 8 mL/hour for 50 hours. Both groups received a standardized multimodal analgesic regimen, including iPACK (infiltration between the popliteal artery and posterior capsule of the knee) block, periarticular infiltration (PAI), and oral pain medications. The primary outcome was opioid consumption during the 24-48 hour postoperative period. Post-anesthesia care unit (PACU) opioid consumption was the single prespecified secondary outcome registered at ClinicalTrials.gov; all other outcomes were pre-planned exploratory analyses prespecified in the Institutional Review Board protocol. RESULTS: There was no statistically significant difference in opioid consumption during the 24-48 hour postoperative period between the continuous infusion and single-injection groups (median (IQR) 30 (15-60) mg vs 38.8 (22.9-69.4) mg; 95% CI of the median difference -22.50 to 7.00 mg; p=0.213). For the prespecified secondary outcome, opioid consumption in the PACU also did not differ significantly between groups (22.5 (16.2-30) mg vs 15 (15-30) mg; 95% CI of the median difference 0.00 to 13.50 mg; p=0.081). Catheter-associated buckling occurred in 7% of the continuous infusion group versus 0% in the single-injection group; all events were transient. No statistically significant differences were observed in patient satisfaction, length of hospital stay, or functional recovery. CONCLUSIONS: Continuous adductor canal catheter infusion, initiated at the resolution of spinal anesthesia, did not reduce opioid consumption in the 24-48 hour postoperative period following primary TKA within a comprehensive multimodal analgesic regimen including perineural dexamethasone, iPACK block, PAI, oral pain medications, and continuous telemedicine-based pain consultation. TRIAL REGISTRATION NUMBER: NCT03747146.

来源:Reg Anesth Pain Med,查看原文。版权归原作者所有。

引用

  1. Kim DH, Beathe J, Wetmore DS, et al. Single-injection adductor canal block with perineural dexamethasone versus continuous adductor canal catheter for total knee arthroplasty: a randomized controlled trial. Reg Anesth Pain Med. 2026. PMID: 42242837. doi:10.1136/rapm-2026-107719

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。